Heer Medical Participates in the 2024 Wuhan Medical-Enterprise Integration Development Promotion Conference

To further enhance medical-enterprise cooperation and exchange, enrich medical diagnostic service methods and pharmaceutical distribution product categories, and promote the clustered development of the entire in-vitro diagnostics industry chain, the 2024 Wuhan Medical-Enterprise Integration Development Promotion Conference (In-Vitro Diagnostics Special Session) was successfully held in Wuhan on May 9, 2024.

This conference organized enterprises along the in-vitro diagnostics industry chain, pharmaceutical distribution companies, and medical institutions for a development promotion meeting. The goal was to further enhance medical-enterprise cooperation and exchange, expand "locally produced, locally used" products, enrich medical diagnostic service methods and pharmaceutical distribution product types, and promote the clustered development of the entire in-vitro diagnostics industry chain.

As a pioneer in the in-vitro diagnostics industry, Wuhan Heer Medical was invited to attend this conference, aiming to actively promote the localized application of the company's products. Since its establishment in 2006, Heer Medical has comprehensively deployed a cytopathology platform featuring DNA ploidy quantitative detection and AI-assisted cell morphology diagnostic technology, as well as an immunohistochemistry platform represented by HPV E6/E7 protein and p16/Ki-67 dual-stain detection. The company is committed to becoming an integrated comprehensive supplier providing early tumor screening equipment, supporting software and reagents, related technical support, as well as value-added services such as personnel training and equipment maintenance.